Franson T R, Quebbeman E J, Whipple J, Thomson R, Bubrick J, Rosenberger S L, Ausman R K
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226.
Crit Care Med. 1988 Sep;16(9):840-3. doi: 10.1097/00003246-198809000-00004.
Aminoglycoside (gentamicin, tobramycin) dosage regimens and subsequent serum concentrations were compared in 30 patients treated initially using traditional physician-determined methods and then switched to a pharmacokinetic-based treatment program. Patients received more drug during the kinetic phase (median 5 mg/kg) than during the traditional phase (median 3.6 mg/kg) and achieved greater peak serum concentration (5.9 vs. 4.4 micrograms/ml). Seventy-three percent of kinetic peak values but only 27% of traditional peak values exceeded 5.0 micrograms/ml. Trough concentrations were comparable in both phases of study and no nephrotoxicity was observed. This pharmacokinetic-based management program achieved more consistently greater therapeutic peak concentrations and provided more individualized therapy than did physicians. The use of pharmacokinetic consultants may be of benefit in administering safely optimal aminoglycoside therapy.
对30例患者的氨基糖苷类药物(庆大霉素、妥布霉素)给药方案及随后的血清浓度进行了比较。这些患者最初采用传统的医生确定方法进行治疗,随后改用基于药代动力学的治疗方案。患者在药代动力学阶段接受的药物更多(中位数为5mg/kg),高于传统阶段(中位数为3.6mg/kg),且血清峰值浓度更高(5.9对4.4μg/ml)。药代动力学阶段73%的峰值浓度超过5.0μg/ml,而传统阶段仅为27%。两个研究阶段的谷浓度相当,且未观察到肾毒性。与医生的治疗相比,这种基于药代动力学的管理方案能更持续地达到更高的治疗峰值浓度,并提供更个体化的治疗。使用药代动力学顾问可能有助于安全地给予最佳的氨基糖苷类药物治疗。